JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors.
Gao SP, Chang Q, Mao N, Daly LA, Vogel R, Chan T, Liu SH, Bournazou E, Schori E, Zhang H, Brewer MR, Pao W, Morris L, Ladanyi M, Arcila M, Manova-Todorova K, de Stanchina E, Norton L, Levine RL, Altan-Bonnet G, Solit D, Zinda M, Huszar D, Lyden D, Bromberg JF.
Gao SP, et al. Among authors: brewer mr.
Sci Signal. 2016 Mar 29;9(421):ra33. doi: 10.1126/scisignal.aac8460.
Sci Signal. 2016.
PMID: 27025877
Free PMC article.